Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market
21 February 2019 - 10:00PM
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage
biopharmaceutical company dedicated to transforming the lives of
patients and families affected by complement mediated diseases,
today announced the expansion into a second office located at 1777
Sentry Parkway West in Blue Bell, Pa. The approximately 12,000
square-feet office space will serve as Achillion’s executive
offices and clinical operations base while the Company maintains
its current significant research presence in New Haven,
Connecticut.
“Achillion continues to expand our clinical
development, clinical operations and regulatory teams as we
accelerate our oral, small molecule complement inhibitor programs
into late-stage development and commercialization,” said Joe
Truitt, President and Chief Executive Officer at Achillion. “We
believe this additional space and proximity to talented and
innovative individuals in the Philadelphia area will bolster our
growing commercial capabilities as we develop treatments for
patients with complement-mediated diseases.”
The new space opened for operations on January
1, 2019.
About Achillion
PharmaceuticalsAchillion Pharmaceuticals,
Inc. (Nasdaq: ACHN) is a clinical-stage biopharmaceutical
company focused on advancing its oral factor D inhibitors
into late-stage development and commercialization. Factor
D is an essential enzyme in the alternative pathway of the
complement system, a part of the innate immune system. Achillion is
initially focusing its drug development activities on alternative
pathway-mediated diseases where there are no approved therapies or
where existing therapies are inadequate for patients. Potential
indications being evaluated for its compounds include paroxysmal
nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and immune
complex mediated membranoproliferative glomerulonephritis
(IC-MPGN). Each of the product candidates in the Company’s oral
factor D portfolio was discovered in its laboratories and is wholly
owned. To advance its investigational product candidates into
Phase 3 clinical trials and commercialization, the Company plans to
work closely with key stakeholders including patients, payors,
regulators and healthcare professionals. More information is
available at http://www.achillion.com.
Corporate
Communications:Susanne Heinzinger Senior VP, Corporate
CommunicationsAchillion Pharmaceuticals, Inc.Tel.
215-709-3055sheinzinger@achillion.com
Media:Jon PappasMedia RelationsW2O GroupTel.
(646) 847-0303jpappas@w2ogroup.com
Source: Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2024 to May 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Achillion Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles